Erythrocytapheresis for Chronic Mountain Sickness

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorThird Military Medical University

About this trial

The study aims to explore the efficacy and safety of erythrocytapheresis in chronic mountain sickness

Eligibility criteria

Qualifiers

Age ≥18 years;

High-altitude residents or long-term dwellers (continuous residence at ≥2500 meters above sea level for at least 1 year), with no travel history to low-altitude areas in the past 3 months;

Hemoglobin (Hb): Men: ≥210 g/L, Women: ≥190 g/L; at least one symptom or sign: headache, dizziness, dyspnea, palpitations, sleep disturbances, fatigue, localized cyanosis, burning sensation in palms/soles, venous dilatation, muscle/joint pain, loss of appetite, poor concentration, or memory changes; CMS total score ≥6;

Written informed consent obtained from patients or their legal representatives.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Erythropheresis

Treatment groups

112 Participants
are divided into 2 treatment groups